JP2016128441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128441A5 JP2016128441A5 JP2016001684A JP2016001684A JP2016128441A5 JP 2016128441 A5 JP2016128441 A5 JP 2016128441A5 JP 2016001684 A JP2016001684 A JP 2016001684A JP 2016001684 A JP2016001684 A JP 2016001684A JP 2016128441 A5 JP2016128441 A5 JP 2016128441A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antagonist antibody
- binding portion
- madcam antagonist
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 20
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 20
- 239000000090 biomarker Substances 0.000 claims 17
- 206010009900 Colitis ulcerative Diseases 0.000 claims 10
- 208000011231 Crohn disease Diseases 0.000 claims 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 6
- -1 sMAdCAM Proteins 0.000 claims 6
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims 5
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 5
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 5
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims 5
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002550 fecal effect Effects 0.000 claims 5
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 4
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 4
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 4
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 claims 4
- 102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 claims 4
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 4
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims 4
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 4
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 4
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 4
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 4
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims 4
- 101000686909 Homo sapiens Resistin Proteins 0.000 claims 4
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 4
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 claims 4
- 108050003558 Interleukin-17 Proteins 0.000 claims 4
- 102000013691 Interleukin-17 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 108010002586 Interleukin-7 Proteins 0.000 claims 4
- 108090001007 Interleukin-8 Proteins 0.000 claims 4
- 102000004890 Interleukin-8 Human genes 0.000 claims 4
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 4
- 101710187853 Macrophage metalloelastase Proteins 0.000 claims 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 4
- 108090000630 Oncostatin M Proteins 0.000 claims 4
- 102100031942 Oncostatin-M Human genes 0.000 claims 4
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 claims 4
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 4
- 101710110949 Protein S100-A12 Proteins 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102100037889 Regenerating islet-derived protein 4 Human genes 0.000 claims 4
- 101710193245 Regenerating islet-derived protein 4 Proteins 0.000 claims 4
- 102100024735 Resistin Human genes 0.000 claims 4
- 102000058242 S100A12 Human genes 0.000 claims 4
- 102100030416 Stromelysin-1 Human genes 0.000 claims 4
- 101710108790 Stromelysin-1 Proteins 0.000 claims 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 4
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 102100028848 Stromelysin-2 Human genes 0.000 claims 3
- 101710108792 Stromelysin-2 Proteins 0.000 claims 3
- 230000009286 beneficial effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- 108700012434 CCL3 Proteins 0.000 claims 2
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000023002 juvenile spondyloarthropathy Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101877P | 2015-01-09 | 2015-01-09 | |
| US62/101,877 | 2015-01-09 | ||
| US201562263197P | 2015-12-04 | 2015-12-04 | |
| US62/263,197 | 2015-12-04 | ||
| US201562263910P | 2015-12-07 | 2015-12-07 | |
| US62/263,910 | 2015-12-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173121A Division JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128441A JP2016128441A (ja) | 2016-07-14 |
| JP2016128441A5 true JP2016128441A5 (enExample) | 2019-08-29 |
| JP6779621B2 JP6779621B2 (ja) | 2020-11-04 |
Family
ID=55275128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016001684A Active JP6779621B2 (ja) | 2015-01-09 | 2016-01-07 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
| JP2020173121A Active JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173121A Active JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10851163B2 (enExample) |
| EP (2) | EP3242684B1 (enExample) |
| JP (2) | JP6779621B2 (enExample) |
| KR (1) | KR102756784B1 (enExample) |
| CN (3) | CN114732899A (enExample) |
| AU (2) | AU2016205852B2 (enExample) |
| BR (1) | BR112017014793A2 (enExample) |
| CA (1) | CA2916283C (enExample) |
| CL (1) | CL2017001756A1 (enExample) |
| EA (1) | EA037288B1 (enExample) |
| ES (1) | ES2927958T3 (enExample) |
| IL (1) | IL253247B (enExample) |
| MA (1) | MA41314A (enExample) |
| MX (1) | MX385589B (enExample) |
| SG (1) | SG11201705604WA (enExample) |
| WO (1) | WO2016110806A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170360926A1 (en) * | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer | Dosage regimen for madcam antagonists |
| MX2019013517A (es) * | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| SG11202000298VA (en) | 2017-07-14 | 2020-02-27 | Pfizer | Antibodies to madcam |
| CN108118093A (zh) * | 2018-03-06 | 2018-06-05 | 谢琳 | Linc00426在制备骨肉瘤转移诊断产品中的用途 |
| US20210030868A1 (en) * | 2019-07-29 | 2021-02-04 | Cai Gu Huang | Formulation of antibody based drugs for treating lung cancer by inhalation |
| CN113789328A (zh) * | 2021-09-16 | 2021-12-14 | 中国人民解放军海军军医大学 | lncRNA及其在免疫调控及免疫相关疾病诊治中的应用 |
| CN114164211B (zh) * | 2021-09-16 | 2024-02-27 | 中国人民解放军海军军医大学 | lncRNA及其在肿瘤诊断、治疗和预后判断中的应用 |
| CN116631510B (zh) * | 2022-10-28 | 2024-01-12 | 中国人民解放军军事科学院军事医学研究院 | 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置 |
| WO2024110868A1 (en) | 2022-11-22 | 2024-05-30 | Takeda Pharmaceutical Company Limited | DOSAGE REGIMEN OF MAdCAM-1 ANTIBODY FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| WO2004081049A1 (en) * | 2003-03-10 | 2004-09-23 | Auckland Uniservices Limited | Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof |
| CN1956738B (zh) * | 2004-01-09 | 2013-05-29 | 辉瑞大药厂 | MAdCAM抗体 |
| DK1865986T3 (en) * | 2005-03-08 | 2016-04-11 | Pfizer Prod Inc | The anti-CTLA-4 antibody compositions |
| ATE483732T1 (de) | 2005-07-08 | 2010-10-15 | Pfizer Ltd | Madcam-antikörper |
| BRPI0612645A2 (pt) | 2005-07-08 | 2010-11-23 | Pfizer Ltd | uso de anticorpos anti-madcam para o tratamento de doença celìaca e espru tropical |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| DE102010013830A1 (de) * | 2010-03-26 | 2011-09-29 | Carl Zeiss Microlmaging Gmbh | Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe |
| EP3495814A3 (en) * | 2013-03-27 | 2019-07-17 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer | Dosage regimen for madcam antagonists |
-
2015
- 2015-12-23 CA CA2916283A patent/CA2916283C/en active Active
-
2016
- 2016-01-05 MA MA041314A patent/MA41314A/fr unknown
- 2016-01-06 CN CN202111331779.1A patent/CN114732899A/zh active Pending
- 2016-01-06 BR BR112017014793A patent/BR112017014793A2/pt not_active Application Discontinuation
- 2016-01-06 SG SG11201705604WA patent/SG11201705604WA/en unknown
- 2016-01-06 KR KR1020177021819A patent/KR102756784B1/ko active Active
- 2016-01-06 US US15/542,110 patent/US10851163B2/en active Active
- 2016-01-06 EP EP16702586.5A patent/EP3242684B1/en active Active
- 2016-01-06 WO PCT/IB2016/050047 patent/WO2016110806A2/en not_active Ceased
- 2016-01-06 ES ES16702586T patent/ES2927958T3/es active Active
- 2016-01-06 AU AU2016205852A patent/AU2016205852B2/en active Active
- 2016-01-06 CN CN202111331776.8A patent/CN114377125A/zh active Pending
- 2016-01-06 EP EP22179107.2A patent/EP4112079A1/en active Pending
- 2016-01-06 MX MX2017009047A patent/MX385589B/es unknown
- 2016-01-06 EA EA201791227A patent/EA037288B1/ru unknown
- 2016-01-06 CN CN201680014443.3A patent/CN107427576A/zh active Pending
- 2016-01-07 JP JP2016001684A patent/JP6779621B2/ja active Active
-
2017
- 2017-06-29 IL IL253247A patent/IL253247B/en unknown
- 2017-07-03 CL CL2017001756A patent/CL2017001756A1/es unknown
-
2020
- 2020-10-14 JP JP2020173121A patent/JP7142200B2/ja active Active
- 2020-11-30 US US17/107,228 patent/US11884726B2/en active Active
-
2021
- 2021-10-12 AU AU2021250850A patent/AU2021250850B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016128441A5 (enExample) | ||
| JP7153775B2 (ja) | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 | |
| US12018086B2 (en) | Kit comprising contiguous nucleobases, including position 76, of RS5745994 | |
| Smolen et al. | Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial | |
| JP7177868B2 (ja) | 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法 | |
| Colman et al. | Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease | |
| JP2013508687A (ja) | 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法 | |
| Cludts et al. | Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab | |
| TW201307845A (zh) | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 | |
| Higham et al. | Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease | |
| Balandraud et al. | Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis-A three years retrospective study | |
| EP3446127A2 (en) | Biomarkers and methods for assessing response to inflammatory disease therapy | |
| Quintana-Duque et al. | Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study | |
| Dreesen et al. | Pharmacokinetic modeling and simulation of biologicals in inflammatory bowel disease: the dawning of a new era for personalized treatment | |
| JP2018504584A (ja) | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 | |
| Festen et al. | How will insights from genetics translate to clinical practice in inflammatory bowel disease? | |
| Martínez-Feito et al. | Optimal concentration range of golimumab in patients with axial spondyloarthritis | |
| Eder et al. | Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies | |
| US20250208140A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| Wang et al. | The relationship between hepatitis B virus serum DNA, RNA and quantitative hepatitis B surface antigen, and the predictive value for mother‐to‐child transmission: an observational cohort study | |
| US20240118278A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| Yang et al. | Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients | |
| Li et al. | A Risk Prediction Model for the Development of Rheumatoid Arthritis, Sjögren's Syndrome, Systemic Sclerosis in Patients With Systemic Lupus Erythematosus: Multicenter Approaches | |
| US20240371490A1 (en) | Advanced modeling for biologics | |
| Kizilkaya et al. | Risk of hepatitis B reactivation in rheumatic patients receiving tocilizumab treatment |